Pediatrix Medical Group, Inc. (NYSE:MD) Receives $16.75 Consensus Target Price from Analysts

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $16.75.

Several research firms have commented on MD. UBS Group lifted their target price on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a "neutral" rating in a research report on Friday, February 21st. StockNews.com upgraded Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research note on Wednesday, January 22nd. Finally, Truist Financial decreased their price objective on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a report on Friday, April 11th.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. purchased a new stake in Pediatrix Medical Group in the 4th quarter worth approximately $35,492,000. American Century Companies Inc. grew its position in Pediatrix Medical Group by 628.2% during the fourth quarter. American Century Companies Inc. now owns 1,739,323 shares of the company's stock worth $22,820,000 after buying an additional 1,500,485 shares in the last quarter. Oberweis Asset Management Inc. purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at about $6,122,000. Renaissance Technologies LLC grew its holdings in shares of Pediatrix Medical Group by 117.4% during the fourth quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock worth $11,005,000 after purchasing an additional 453,000 shares in the last quarter. Finally, Boston Partners raised its stake in Pediatrix Medical Group by 25.2% in the fourth quarter. Boston Partners now owns 1,956,353 shares of the company's stock valued at $25,922,000 after purchasing an additional 393,600 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Stock Up 12.0 %

Shares of MD traded up $1.56 on Monday, reaching $14.51. The company's stock had a trading volume of 1,381,420 shares, compared to its average volume of 847,675. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $17.67. The stock has a market capitalization of $1.25 billion, a PE ratio of -12.09, a PEG ratio of 1.74 and a beta of 1.26. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The firm has a fifty day moving average of $13.70 and a 200-day moving average of $14.00.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.37 by $0.12. The firm had revenue of $502.36 million during the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. Equities analysts predict that Pediatrix Medical Group will post 1.38 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.